All In Biotech

Drug Trial Radar · NCT06844799

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate Efficacy and Safety of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants with Moderate-to-severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Jun 10, 2025

Primary completion

Mar 31, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.

Conditions

  • Moderate-to-severe Plaque Psoriasis

Interventions

  • HS-20137Drug

    HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.

  • Placebo&HS-20137Drug

    Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 90 Percent or AboveTime frame: At week 16
  2. Physician Global Assessment (PGA) score of 0/1Time frame: At week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.